Saturday 17 October 2026
Export CRSP’s income statement to Excel — free account
CRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1,041.4%, EPS grew 60.8% and free cash flow grew 26.2%, each against the same quarter a year earlier.
49.30
2.22
−4.31%
Follow CRSP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
154.35 | 1,343.49 | 1,113.61 | 393.06 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(69.92) | (50.95) | (41.96) | (63.04) | |
P/B ratio |
3.09 | 2.45 | 2.52 | 3.01 | |
Price to Tangible BV |
3.09 | 2.45 | 2.52 | 3.01 | |
EV/Sales |
110.31 | 845.25 | 661.18 | 260.28 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(13.98) | (8.60) | (6.78) | (9.43) | |
EV/FCF |
(13.95) | (8.58) | (6.76) | (9.39) | |
Quick Ratio |
16.10 | 13.25 | 17.92 | 17.79 | |
Current Ratio |
16.22 | 13.32 | 17.96 | 17.85 | |
Net Debt/EBITDA |
15.01 | 13.25 | 14.74 | 15.74 | |
Debt/Assets |
0.00% | 0.00% | 21.48% | 22.11% | |
Debt/Equity |
0.00 | 0.00 | 0.32 | 0.34 | |
Asset Turnover |
0.02 | 0.00 | 0.00 | 0.01 | |
Operating CF/Net income |
0.80 | 0.71 | 0.89 | 0.92 | |
Capex/Depreciation |
(0.02) | (0.09) | (0.12) | (0.15) | |
Research and Development Expense of Revenue |
6,625.65% | 9,667.36% | 4,703.29% | 683.87% | |
Selling, General and Administrative Expense of Revenue |
1,904.50% | 2,129.51% | 1,178.53% | 172.41% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,867.72% | 2,092.13% | 1,119.62% | 170.08% | |
Graham Net Nets |
0.27 | 0.35 | 0.34 | 0.28 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.63%) | (12.43%) | (13.08%) | (8.73%) | |
Free Cash Flow Yield |
(5.12%) | (7.34%) | (8.78%) | (7.05%) | |
Revenue per Share |
0.01 | 0.01 | 0.02 | 0.11 | |
Operating CF per Share |
(0.93) | (1.03) | (1.13) | (0.87) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.93) | (1.03) | (1.14) | (0.87) | |
Cash per Share |
20.98 | 21.97 | 25.42 | 24.50 | |
Shareholders Equity per Share |
20.98 | 21.37 | 18.89 | 18.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
20.98 | 21.37 | 18.89 | 18.10 | |
Free Cash Flow |
(84.71) | (93.07) | (109.40) | (84.15) | |
Working Capital |
1,810.14 | 1,836.55 | 2,312.08 | 2,238.87 | |
Capital Expenditures |
(0.07) | (0.52) | (0.50) | (0.65) | |
Net Current Asset Value |
1,599.77 | 1,642.24 | 1,537.10 | 1,467.55 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.08 | 0.60 | 0.35 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
13.69 | 12.92 | 13.36 | 10.53 | |
Average Assets |
2,250.72 | 2,253.64 | 2,445.96 | 2,340.24 | |
Average Common Equity |
1,927.82 | 1,926.95 | 1,821.86 | 1,728.84 |
Columns are period end dates